|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||30.60 - 30.60|
|52-week range||30.60 - 38.76|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||9.03|
|Forward dividend & yield||1.12 (3.30%)|
|Ex-dividend date||29 June 2022|
|1y target est||N/A|
Dentsu Group Inc. (Tokyo: 4324) (ISIN: JP3551520004) President & CEO: Hiroshi Igarashi; Head Office: Tokyo; Capital: 74,609.81 million yen) announced today that it has entered an agreement to acquire Pexlify, a leading Salesforce consultancy based in the UK and Ireland. Pexlify will join Merkle, a leading technology-enabled, data-driven customer experience management (CXM) company within Dentsu Group's international business, Dentsu International.
NEW YORK, May 10, 2022--As part of its ambition and commitment to unlock opportunities for growth and good across the entire healthcare ecosystem, dentsu health announced today two key senior appointments. To elevate dentsu health’s research and audience capabilities, Data Scientist Olympia Mantsios has been appointed Global VP Data & Analytics. And, to accelerate the transformation of dentsu health’s product offerings, Lynda Gordon will join as SVP, Product Development.
TORONTO, April 28, 2022--Dentsu Canada announced today the merger of Antibody, Canada’s premier full-service communications agency, with dentsu health. The merger follows on the heels of rapid growth for the global healthcare solution.